Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Divestments Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Growth Metrics

Pharma-Bio Serv (PBSV) Long-Term Debt Issuances (2020)

Pharma-Bio Serv filings provide 1 years of Long-Term Debt Issuances readings, the most recent being $1.9 million for Q2 2020.

On a quarterly basis, Long-Term Debt Issuances changed N/A to $1.9 million in Q2 2020 year-over-year; TTM through Oct 2020 was $1.9 million, a N/A change, with the full-year FY2020 number at $1.9 million, changed N/A from a year prior.
Long-Term Debt Issuances hit $1.9 million in Q2 2020 for Pharma-Bio Serv.
In the past five years, Long-Term Debt Issuances ranged from a high of $1.9 million in Q2 2020 to a low of $1.9 million in Q2 2020.